ceritinib
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
ALK Positive Malignancies
Conditions
ALK Positive Malignancies
Trial Timeline
Dec 11, 2015 → Jun 9, 2027
NCT ID
NCT02584933About ceritinib
ceritinib is a approved stage product being developed by Novartis for ALK Positive Malignancies. The current trial status is active. This product is registered under clinical trial identifier NCT02584933. Target conditions include ALK Positive Malignancies.
What happened to similar drugs?
1 of 20 similar drugs in ALK Positive Malignancies were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05100134 | Pre-clinical | Active |
| NCT02584933 | Approved | Active |
| NCT02638909 | Phase 2 | Terminated |
| NCT02513667 | Phase 2 | Terminated |
| NCT02289144 | Phase 2 | Withdrawn |
| NCT02343679 | Phase 2 | Withdrawn |
| NCT02299505 | Phase 1 | Completed |
| NCT02336451 | Phase 2 | Completed |
| NCT02186821 | Phase 2 | Terminated |
| NCT01742286 | Phase 1 | Completed |
Competing Products
20 competing products in ALK Positive Malignancies